Zonisamide for Canine Idiopathic Epilepsy: Efficacy, Tolerability, and Therapeutic Drug Monitoring

Bottom line

• Zonisamide (ZNS) is a sulfonamide-derived, newer-generation antiseizure medication used off-label in canine idiopathic epilepsy (IE). As of July 2026, the largest dataset — a 207-dog retrospective therapeutic-drug-monitoring (TDM) cohort — reports 59% responders on monotherapy [1].
• In a prospective multicenter trial of 56 newly-diagnosed, ASM-naive dogs, 76% (40/53 evaluable) achieved a ≥50% reduction in seizure frequency and 55% (29/53) achieved seizure freedom over 12 weeks of monotherapy [2].
• An evidence-based canine TDM reference interval of 10–55 mcg/mL is proposed [1] — broader than the human interval of 10–40 mcg/mL; responder mean trough was 18.9 mcg/mL (range 8.0–48.0) in the prospective cohort [2].
• Adverse effects in dogs are generally mild and transient (13% incidence; no discontinuations, no clinically relevant lab changes) [2]; idiosyncratic hepatotoxicity and renal tubular acidosis are described in review/case literature but were not quantified in these trials.
• Feline evidence is thinner and retrospective: a 57-cat multicenter cohort found a median decrease of one seizure/month (P = .001) with a distinct AE pattern (sedation and hyporexia each 17%) [3]. ZNS is not FDA-approved for veterinary use in the U.S. — dose from a current formulary, not from any figure here.

Drug facts

• Class / MOA — Sulfonamide-derived antiseizure medication. Blocks voltage-gated sodium channels and T-type calcium channels; may enhance GABAergic activity. Broad, non-benzodiazepine mechanism.
• Primary indication (veterinary) — Monotherapy or adjunctive therapy for canine idiopathic (non-structural) epilepsy; off-label consideration in cats when phenobarbital is unsuitable or insufficient [3].
• Human labeling — Approved as adjunctive therapy for partial seizures in humans; the veterinary use described here is entirely off-label.
• Dosing / PK — Relatively predictable, approximately linear pharmacokinetics support once- or twice-daily dosing; individual clearance variation makes TDM valuable for dose optimization [1]. Exact mg/kg starting doses and titration steps are formulary matters (e.g., Plumb's) and are intentionally out of scope here.
• Approval status — Not FDA-approved for dogs or cats in the United States.
• Key contraindications / cautions — Sulfonamide hypersensitivity; pre-existing hepatic or renal compromise warrants caution given reported idiosyncratic hepatotoxicity and renal tubular acidosis. Establish baseline chemistry/CBC and monitor periodically.

Does zonisamide work? Efficacy in canine idiopathic epilepsy

Two complementary JVIM datasets frame current canine efficacy, one retrospective (long-horizon, real-world) and one prospective (newly-diagnosed, protocolized).

The 207-dog retrospective cohort (Thungrat et al., a decade of Auburn University TDM data, 2011–2021) is the largest ZNS monotherapy efficacy dataset [1]. Dogs with non-structural epilepsy were classified by International Veterinary Epilepsy Task Force (IVETF) response categories: 59% (n=123) were responders — 29% achieving seizure freedom (category 1) and 30% partial response (category 2) — while 41% (n=84) were non-responders (category 3; between-group difference P < .01). Because the cohort is retrospective TDM-library-derived, it characterizes real-world responders rather than a controlled efficacy estimate.

The 56-dog prospective multicenter open-label trial (Saito et al., Japan; all ASM-naive, ≥2 seizures in 12 weeks) provides the cleaner newly-diagnosed signal [2]. Over 12 weeks, 76% (40/53 evaluable) achieved ≥50% seizure reduction and 55% (29/53) achieved seizure freedom. These figures are broadly consistent with what is reported for phenobarbital as first-line monotherapy, though the study was uncontrolled.

Neutral synthesis: the two designs converge on a responder rate in the ~59–76% range, with the higher end reflecting a protocolized, treatment-naive population and the lower end reflecting a broad real-world cohort that includes harder-to-control and longer-followed dogs. Neither is a randomized comparative trial, so the numbers bound expectations rather than rank ZNS against alternatives.

How does zonisamide compare to phenobarbital and other first-line ASMs?

Direct head-to-head canine trials are limited, so comparison rests on cross-study inference and tolerability profile rather than on randomized data.

• Efficacy — ZNS responder rates (59–76% [1][2]) are in the same range commonly cited for phenobarbital first-line monotherapy, but no prospective randomized comparison establishes superiority or non-inferiority.
• Safety trade-off — The principal differentiator is the AE profile. Phenobarbital carries recognized dose-dependent hepatotoxicity risk with chronic administration; ZNS showed no clinically relevant chemistry/haematology changes in the prospective dog cohort [2]. This favors ZNS as a consideration where hepatic risk is a concern — with the caveat that idiosyncratic ZNS hepatotoxicity still occurs and prospective comparative safety data are lacking.
• Where it sits — ZNS is used first- or second-line as monotherapy and as add-on in refractory cases. For sibling first-line agents with their own approval and evidence base, see the potassium bromide and imepitoin reviews.

Therapeutic drug monitoring: the proposed 10–55 mcg/mL canine reference interval

Before these studies, canine ZNS TDM lacked a validated reference interval, forcing extrapolation from the human 10–40 mcg/mL range. Thungrat et al. derived a proposed canine reference interval of 10–55 mcg/mL from responders' plasma concentrations [1] — deliberately broader than the human interval to reflect species pharmacokinetic differences and IVETF-defined response.

Supporting concentration data from the prospective cohort: responders had a mean trough of 18.9 mcg/mL (range 8.0–48.0 mcg/mL) [2], sitting comfortably inside the proposed interval. Together these give a more actionable framework than extrapolated human data alone.

Caveat on strength of evidence: the interval derives from a retrospective design, so confidence intervals are wide and the range is a starting framework, not a hard target. Use TDM to guide titration — especially in non-responders or dogs showing possible toxicity — while adjusting primarily to clinical seizure response.

Safety and adverse effects

Dogs. In the prospective 56-dog trial, AEs occurred in 7/56 (13%): reduced activity, decreased appetite, vomiting, hindlimb weakness, soft stools, or constipation [2]. All were mild and temporary; none required discontinuation, and standard chemistry/haematology showed no clinically relevant changes. Idiosyncratic reactions — hepatotoxicity and renal tubular acidosis — appear in case series and review literature but were not quantified within these trial datasets, so baseline and periodic bloodwork remains prudent.

Cats. The 57-cat retrospective cohort reported a distinct AE pattern: hyporexia (17%), sedation (17%), ataxia (11%), and emesis (5%), with a few cats developing mild nonregenerative anemia, mild metabolic acidosis, or mild increases in ALT and ALP [3]. Overall the authors judged ZNS well tolerated in most cats, but the sedation/hyporexia signal is more prominent than in the canine data and warrants explicit owner counseling and monitoring when extrapolating to feline patients.

Special populations: zonisamide in cats

Evidence-based antiseizure options in cats beyond phenobarbital remain limited, and the 57-cat multicenter retrospective cohort (Djani et al.) is one of the larger feline-specific datasets to date [3]. Across all 57 cats, oral ZNS was associated with a median decrease of one seizure per month (P = .001) and a similar reduction in seizure-days per month. In the idiopathic-epilepsy subgroup, median reductions were larger (one and two, respectively). The authors concluded ZNS was well tolerated and efficacious in controlling seizure activity in most cats.

Interpretation: the feline data are retrospective and uncontrolled — they describe association, not proven efficacy — but they support ZNS as a reasonable consideration when phenobarbital is unsuitable or insufficient. The feline AE pattern differs from dogs (above), so feline use is an extrapolation that should be paired with species-specific monitoring and formulary-derived dosing.

Contraindications, precautions & PK

• Sulfonamide hypersensitivity — ZNS is sulfonamide-derived; avoid in patients with known sulfonamide hypersensitivity.
• Hepatic reserve — Idiosyncratic hepatotoxicity is reported; obtain baseline liver enzymes and monitor. In cats, mild ALT/ALP increases were observed in a minority [3].
• Renal / acid-base — Renal tubular acidosis is described in dogs; mild metabolic acidosis was seen in some cats [3]. Consider acid-base status in at-risk patients.
• Haematology — Mild nonregenerative anemia occurred in a few cats [3]; include CBC in monitoring.
• Pharmacokinetics — Approximately linear PK with once- or twice-daily dosing; inter-individual clearance variation is the core rationale for TDM [1]. Titrate to clinical response, using trough concentrations against the proposed 10–55 mcg/mL canine interval [1] as a guide, not a mandate.
• Formulary dependence — Species-specific mg/kg dosing, monitoring intervals, and full contraindication lists belong to a current formulary (e.g., Plumb's Veterinary Drug Handbook) and are out of scope for this evidence summary.

Practical decision support

• Candidate selection — Reasonable first- or second-line monotherapy for canine IE, and a first consideration in dogs where phenobarbital hepatotoxicity risk is a concern [2]. In cats, consider when phenobarbital is unsuitable or insufficient, counseling owners on the sedation/hyporexia signal [3].
• Baseline — Chemistry (including liver enzymes) and CBC before starting; document seizure frequency to define a response denominator.
• Titration & monitoring — Adjust to clinical seizure response; use TDM to interpret non-response or suspected toxicity, referencing the proposed 10–55 mcg/mL canine interval [1] (responder mean trough ~18.9 mcg/mL [2]). Recheck bloodwork periodically per formulary.
• Setting expectations — Communicate a realistic responder range (~59–76% in dogs [1][2]) and that seizure freedom is achievable in roughly half of newly-diagnosed dogs [2] but not guaranteed.
• Escalation — For refractory cases, ZNS is used adjunctively; revisit diagnosis (structural vs idiopathic) and consider sibling agents (potassium bromide, imepitoin) within a formulary-guided plan.

Frequently Asked Questions

Is zonisamide FDA-approved for dogs or cats? No. Zonisamide is not FDA-approved for veterinary use in the United States and is used off-label in both dogs and cats. It is approved in humans as adjunctive therapy for partial seizures. Dose from a current formulary rather than from published figures.

How effective is zonisamide monotherapy in newly-diagnosed canine idiopathic epilepsy? In a prospective multicenter trial of 56 ASM-naive dogs, 76% (40/53 evaluable) achieved a >=50% reduction in seizure frequency and 55% (29/53) achieved seizure freedom over 12 weeks. A separate 207-dog retrospective cohort reported 59% responders on monotherapy.

What is the proposed therapeutic drug monitoring reference interval for zonisamide in dogs? A 207-dog retrospective TDM cohort proposed a canine reference interval of 10-55 mcg/mL, broader than the human 10-40 mcg/mL. Responder mean trough was 18.9 mcg/mL (range 8.0-48.0). The interval is retrospectively derived, so treat it as a titration guide rather than a hard target.

How does zonisamide compare to phenobarbital for canine epilepsy? Direct randomized comparisons are limited. Zonisamide responder rates (59-76%) are in the range cited for phenobarbital first-line monotherapy, but the main differentiator is safety: zonisamide showed no clinically relevant liver-enzyme changes in a prospective dog cohort, which may favor it where hepatotoxicity risk is a concern. Idiosyncratic zonisamide hepatotoxicity still occurs.

What adverse effects are reported with zonisamide in dogs? In the prospective 56-dog trial, 13% (7/56) had mild, transient effects: reduced activity, decreased appetite, vomiting, hindlimb weakness, soft stools, or constipation. No dog required discontinuation and laboratory panels showed no clinically relevant changes. Idiosyncratic hepatotoxicity and renal tubular acidosis are described in case literature but were not quantified in these trials.

Does zonisamide work in cats, and what side effects should I expect? A 57-cat multicenter retrospective cohort found a median decrease of one seizure per month (P = .001), with larger reductions in the idiopathic-epilepsy subgroup, and judged zonisamide well tolerated in most cats. The data are retrospective and uncontrolled, so they show association rather than proven efficacy. The most common adverse effects were hyporexia (17%), sedation (17%), ataxia (11%), and emesis (5%), with a few cats showing mild nonregenerative anemia, mild metabolic acidosis, or mild ALT/ALP increases.

What is zonisamide's mechanism of action? Zonisamide is a sulfonamide-derived antiseizure medication that blocks voltage-gated sodium channels and T-type calcium channels and may also enhance GABAergic activity. Its approximately linear pharmacokinetics support once- or twice-daily dosing.

Should I use therapeutic drug monitoring when prescribing zonisamide? Yes, TDM is valuable because inter-individual clearance varies. Use trough concentrations against the proposed 10-55 mcg/mL canine interval to interpret non-response or suspected toxicity, while adjusting the dose primarily to clinical seizure response. Obtain baseline chemistry and CBC and recheck periodically per formulary. (Rendered from the FAQ bundle below.)

Changelog

• 2026-06-19: First published (canine evergreen).
• 2026-07-06: Consolidated two dated dispatch updates into this hub — the TDM reference-interval dispatch (Thungrat 207-dog cohort + Saito prospective trial; proposed 10–55 mcg/mL canine RI) and the feline seizure-control dispatch (Djani 57-cat retrospective cohort). Added a dedicated TDM section, a comparator section, an expanded safety section covering species-specific AE patterns, a feline special-populations section, and consolidated contraindications/PK and practical decision-support sections. Each distinct study is cited once ([1] Thungrat, [2] Saito, [3] Djani).